GlassScriptPhysician profile
Michael D Westafer
NPI 1033473913
$4,263.97
in general payments reported to CMS, 2019-2025
22 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $254 · 2021: $475 · 2022: $779 · 2023: $539 · 2024: $965 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,066.49 | 2021-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| New World Medical,INC. | $843.01 | 2021-2025 | Streamline, Ahmed Glaucoma Valve, Clearpath |
| Abbvie INC. | $542.60 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $408.44 | 2019-2021 | |
| Allergan, INC. | $312.72 | 2019-2022 | |
| Rxsight INC | $193.58 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Glaukos Corporation | $166.23 | 2023 | |
| Sun Pharmaceutical Industries INC. | $108.67 | 2019-2021 | |
| Sight Sciences, INC. | $96.31 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $75.07 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.09 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $63.10 | 2025 | Acthar |
| Nova Eye, INC. | $47.29 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.26 | 2025 | Sotyktu |
| Dompe US, INC. | $40.83 | 2019-2025 | Oxervate |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $40.41 | 2024 | Iyuzeh |
| Harrow Eye, LLC | $37.20 | 2025 | Vevye |
| Ivantis, INC | $31.40 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $24.13 | 2021 | |
| Rayner Intraocular Lenses Limited | $19.91 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
| Biotissue Holdings INC. | $18.25 | 2019 | |
| Eyepoint US, INC. | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Westafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.